March 20 (Reuters) – Australian Clinical Labs (ACL.AX) said on Monday it will acquire Healius (HLS.AX) through an all-share takeover, valuing the medical center operator at A$1.52 billion ($1.02 billion).
The pathology firm said it will offer 0.74 share for every Healius share. The offer price represents a discount of about 4.2% to Healius’ last close.
If the deal is successful, Healius’ shareholder will own 68% of the merged entity, the company said in a statement.
In 2020, Healius rejected a $1.3 billion buyout offer from Partners Group, saying at the time it undervalued the medical center operator.
($1 = 1.4896 Australian dollars)
Reporting by Navya Mittal in Bengaluru; Editing by Lisa Shumaker
Our Standards: The Thomson Reuters Trust Principles.